Received: from DB1PEPF000509FB.eurprd03.prod.outlook.com (2603:10a6:10:53e:cafe::2a) by DU6P191CA0063.outlook.office365.com (2603:10a6:10:53e::19) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.20.9769.48 via Frontend Transport; Mon, 13 Apr 2026 09:51:04 +0000 Received: from DU6P191CA0063.EURP191.PROD.OUTLOOK.COM (2603:10a6:10:53e::19) by VI0PR02MB10512.eurprd02.prod.outlook.com (2603:10a6:800:20d::20) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9769.48; Mon, 13 Apr 2026 09:51:04 +0000 Received: from mail1.rit.ee (213.184.53.4) by DB1PEPF000509FB.mail.protection.outlook.com (10.167.242.37) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9769.17 via Frontend Transport; Mon, 13 Apr 2026 09:51:04 +0000 Received: from BESP191MB2978.EURP191.PROD.OUTLOOK.COM (2603:10a6:b10:f2::13) by DU5P191MB2462.EURP191.PROD.OUTLOOK.COM (2603:10a6:10:524::17) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9769.48; Mon, 13 Apr 2026 09:51:00 +0000 Received: from BESP191MB2978.EURP191.PROD.OUTLOOK.COM ([fe80::8b36:d003:62d0:44ef]) by BESP191MB2978.EURP191.PROD.OUTLOOK.COM ([fe80::8b36:d003:62d0:44ef%4]) with mapi id 15.20.9769.046; Mon, 13 Apr 2026 09:51:00 +0000 Received: from VI0PR02MB10512.eurprd02.prod.outlook.com (2603:10a6:800:20d::20) by DB9PR02MB7817.eurprd02.prod.outlook.com with HTTPS; Mon, 13 Apr 2026 09:51:07 +0000 From: "Tervisekassa" To: Cc: "Info - SOM" Subject: =?utf-8?Q?T=C3=A4iendav_sisend_meditsiinilise_t?= =?utf-8?Q?ranspordi_arvelduse_korralduse_k?= =?utf-8?Q?ohta_-_Tervisekassa_PK-45634?= Date: Mon, 13 Apr 2026 12:51:00 +0300 Keywords: Mall Message-ID: <1568447366.14777.1776073860190@a-jira1-p> MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0065_01DCCB45.7F9B0500" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQGlb18Tft+rej4JsOwqoXIFZtQwcA== Authentication-Results: spf=fail (sender IP is 213.184.53.4) smtp.mailfrom=tervisekassa.ee; dkim=pass (signature was verified) header.d=tervisekassa.ee;dmarc=pass action=none header.from=tervisekassa.ee;compauth=pass reason=100 x-ms-traffictypediagnostic: BESP191MB2978:EE_|DU5P191MB2462:EE_|DB1PEPF000509FB:EE_|VI0PR02MB10512:EE_|DB9PR02MB7817:EE_ X-MS-Office365-Filtering-Correlation-Id: c529cc79-f1ad-4860-a017-08de99422dba X-MS-Exchange-AtpMessageProperties: SA|SL X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|3109299003|7049299003|376014|1032899013|69100299015|366016|1800799024|7149299003|52116014|38350700014|56012099003|18002099003|2066899003|8096899003; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:BESP191MB2978.EURP191.PROD.OUTLOOK.COM;PTR:;CAT:NONE;SFS:(13230040)(3109299003)(7049299003)(376014)(1032899013)(69100299015)(366016)(1800799024)(7149299003)(52116014)(38350700014)(56012099003)(18002099003)(2066899003)(8096899003);DIR:OUT;SFP:1102; X-MS-Exchange-Transport-CrossTenantHeadersStamped: DU5P191MB2462 X-MS-Exchange-Transport-CrossTenantHeadersStamped: VI0PR02MB10512 X-MS-Exchange-Organization-ExpirationStartTime: 13 Apr 2026 09:51:04.7285 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: c529cc79-f1ad-4860-a017-08de99422dba X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Incoming X-MS-Exchange-Organization-AuthAs: Anonymous X-MS-Exchange-Organization-AuthSource: DB1PEPF000509FB.eurprd03.prod.outlook.com X-MS-Exchange-Organization-SCL: -1 X-MS-Exchange-Transport-CrossTenantHeadersStripped: DB1PEPF000509FB.eurprd03.prod.outlook.com X-MS-PublicTrafficType: Email X-MS-Office365-Filtering-Correlation-Id-Prvs: 38a8040f-5be7-490c-c38a-08de99422b0b X-Microsoft-Antispam: BCL:0;ARA:13230040|12012899012|35042699022|2092899012|7049299003|3109299003|69100299015|1032899013|7149299003|82310400026|55112099003|8096899003|2066899003|56012099003|16102099003|19002099003; X-Forefront-Antispam-Report: CIP:213.184.53.4;CTRY:EE;LANG:et;SCL:-1;SRV:;IPV:CAL;SFV:NSPM;H:mail1.rit.ee;PTR:mail1.rit.ee;CAT:NONE;SFS:(13230040)(12012899012)(35042699022)(2092899012)(7049299003)(3109299003)(69100299015)(1032899013)(7149299003)(82310400026)(55112099003)(8096899003)(2066899003)(56012099003)(16102099003)(19002099003);DIR:INB; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 13 Apr 2026 09:51:04.5366 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: c529cc79-f1ad-4860-a017-08de99422dba X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthAs: Anonymous X-MS-Exchange-CrossTenant-AuthSource: DB1PEPF000509FB.eurprd03.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: Internet X-MS-Exchange-Transport-EndToEndLatency: 00:00:02.5669011 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9769.044 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: =?us-ascii?Q?wG5MsQ2GkkwhdsfAnvKPzahsta1V+jwWLpF79vI4B41FTUXKsYPZ15rmj1fd?= =?us-ascii?Q?/MvoBwPuC4hNsBRrI/Xu8Id4985hKwcKGUZLwJO6DcFk9ePeePvDhG/ouiQc?= =?us-ascii?Q?KWudsLAYO4VLx71FJ0D9a2/Mc/qRuPMa1b11NZZm4xbAsrCLE4JOBrSDiFHx?= =?us-ascii?Q?PtzPT36j9BA5Be3hXQgWp2VkOJ/Y5I3MLZyjuzOR8xo1Vg+k0JHVnuV60S6v?= =?us-ascii?Q?U+wezgKMh/WxuLIN64L2j09TjfrVIj1ZuTyaCjHGg0K/3phD+YoZREFsuGgp?= =?us-ascii?Q?FelarCYlW0nnG75WsLzKK/f0tmkaAagk3u1I7SoJIt32puIGZuzmaB/c4hK7?= =?us-ascii?Q?lG5rAFbEGFQ4+2HrQpMcFq6xgsGCtuO36snJBPhN0E0WC5+0m+gYCmDBZmrv?= =?us-ascii?Q?cz/qCFNv3fzWXf7sZex4Tx7+Qe1ZGlE3QHpxDbEfOQI55WRtJVDBXkcgo0WI?= =?us-ascii?Q?/aq/d83QygxfsJFFMdUYwS/1oohk5D8O7cd1Mn6DKGsw8vPvL2qF3j4DoZFb?= =?us-ascii?Q?BZqs5T3Y9U0C5ewdmeU4BFHj23L5crwWL8Dpqvb/c4pDdg4L0Coss3BgCmFE?= =?us-ascii?Q?LTKOWiiRx8kbPfu7MJtcM03JKI0N5tiPqQyRYeVe46UAfaQ9gn3UjE/E1xFi?= =?us-ascii?Q?ZU/vCSc4tQtIK5uLEqLUPLEnMmpvwGeNDtM+OkZNTZuABZkK+sQzsyjptjhU?= =?us-ascii?Q?EM1SNIYh1HIZ0HGlBjoffgrXNkB+6XZuB/hgeRQiod9KcCWaF3h +X5NLdJw4?= =?us-ascii?Q?C0DtWUdWwNlLNDxwFWfMJiEA+NAzHlN5EVg9G5dWQ4mY/iS8jftJkwxQx7dw?= =?us-ascii?Q?AGhLuLU8BP1KBUIvRT8Cc4JGzWpPtDLybloJPIZbmsF+qZGkWfqxK8Lqhrho?= =?us-ascii?Q?C8XEG42X4IBgtlUdNBn20rFZGrA8qBboD5uGCC0gJOhjyoV+AgbEIoBf1XMR?= =?us-ascii?Q?ddCjLpwc8BuaDkKzLrXwG1v2z77QlbGlk4x1c5a+EYoYB9w8g+2cL+RVncoy?= =?us-ascii?Q?I1vVVBk2rycRpXfo6LZZj5ZRlbXW+wv9e46Daz+UZUbVnUj9cOio42XqEdCA?= =?us-ascii?Q?tmevMgW9zbkN2ca/Hd4s1FleUIRjfCoLeHW6hSk6a0r4umG6JZmzEsj/FxIG?= =?us-ascii?Q?m+Kz8HjWVMbhkJJgn/vWfA4yEAwF5UXh6r0MGemJHLrlCss2DJapJnz68iMU?= =?us-ascii?Q?TOBZjxssDwTks7vKgf9iCbux9y90KqzDqXdfrkAtPiOXMs47v8J7XHG9Ntca?= =?us-ascii?Q?7MDonCnLtJwMJfGcfNxbE+haEQDF+uhaWqOwoTIHWHtLDGJVpBxWvW+Q3xUJ?= =?us-ascii?Q?tNvCEJ6v3UhcTjjMhpHho+WYcHUS4LFq32mvt0+BrO59nu1PvjkACuh4D3CU?= =?us-ascii?Q?UEHcA3wnhql/iq8aFhzE14WNpsubWxYF8v5R48olfnKG6PMlZRMOb0l/QbvF?= =?us-ascii?Q?24RMp9roGgw8XgPMB3wuy7LM14V21vhZ/oMHAqbSj5LSHJT/nr80bFaae07s?= =?us-ascii?Q?jb7QEdaExq2Iy7icYd6Ibqg6cUt4l07nSyhh/ FWoNFAh4/gq28een/J3Q0/m?= =?us-ascii?Q?YF1sSwb3Kt14niO0C5AeBCGpNFVBDnBC6xmkE+UGVt+CJ1xvULF7z1D3WHQX?= =?us-ascii?Q?nJ/4iXATWYaSBcS5rtxrG4MUHQNKONnc/q5/Avtr4bCbiT0/HPChDUcN/Hyd?= =?us-ascii?Q?dlUlUPDftzjaIxdXs185lwbCMofxTV7Jd4mGzp2QaR+Uvs4+WHiO3H41AaD0?= =?us-ascii?Q?D8JhlB3yVatHQimEnXBkEEk9z1yQcOq23lt8YwIYZXI9L7n4n8EVZvbpyEH2?= =?us-ascii?Q?nNywmoXcI8OXII0IBYAl2MaZw135nBgB2alnLw75kpoaVQDV3SuxLdAtfpTH?= =?us-ascii?Q?fKMpqgmYppChxxdmeGZc9dlW9VPOU2zX7TiWxzJkE2HQwO6G+VoZQD2ThtJD?= =?us-ascii?Q?RdBFSKezHs3Vt+LjNqa3B6ET9DyskgonoTMOZkQjmBEkKurU/rEdbsNyFlSn?= =?us-ascii?Q?rq+UVIxlvdGT9Nbpt8cdl+eDtXI0vA7P3BMXvDggzhSdFojrGyQc3JyQH9x/?= =?us-ascii?Q?dCQsRnwqMkGEgfDF2fWGPN/Vy+F+pG4Iu+5j1O3d0BiV8eheiPBzzsm23Jev?= =?us-ascii?Q?YyChR1tCmcmDuUNaCuRXdkfiw/MXgBT9R/fNlpPuynwwnt2nXCmAH+zOp14c?= =?us-ascii?Q?Vnq2G81vzyvf1SJk6QxxbsfiSl9ToKaT9jxvjNjGioBtu5Y/FXOYpUDtPd2t?= =?us-ascii?Q?xJiKbWtNMIM44pdCmbHkEhNGgm5Qu4De1WSKU809ue3JkFlTWC0OkSuCgVQ2?= =?us-ascii?Q?oIEpV/+HVx0qSrQ9mMTyvWQ DEIH6MDwH0c0DI2zIsM+HR8uVt1teg2v5M83Q?= =?us-ascii?Q?C1EjnoFhHFiTyuz1BZuTdyFMG4dbUmRHLg+UV/bikKHRFWgjGdnLon01gUFm?= =?us-ascii?Q?1dvwuABvKAHpBSxTVyZEdBimevo7i4jAjaj8pJcU5VP5sU0kwBlnnfdgJBy/?= =?us-ascii?Q?K+SdgkkDJmo0mgHr8J6yFl70EcQ/7033CzRUVdzBjhD/hfsyzPugQjHDaPu/?= =?us-ascii?Q?shsdH3omkiSR5oMdY4yqVEhECBclBgr19JaWdH10qSyfpGLiQSKKI9BpiZ/D?= =?us-ascii?Q?Y+OdxscTTSW7KshCvdagi3VLxXbicMOl+Ob60SHm1XLFQsoWDj4q9h7vlZmS?= =?us-ascii?Q?uwX2DbfqjeHiFrD7NSmrVzv1jC/HTqAsvWELTw509w9xPcvQHoqOlbV1vTCc?= =?us-ascii?Q?kg0QEUvTPOfNBp+0lsGWoj5nvrvAtf1VPaUjPGMxVIQCM1nSWeLW0mXlxSQH?= =?us-ascii?Q?IZ8aDqaVHFVDoj9QiD3gjKuFMPfcjnEqV2eipNRx38I/rSZa5CaD3ejEj9EP?= =?us-ascii?Q?K4F4ho2E6lJvzbsiLciOsUk3EDVomeRex/cIuDOT6/HKwAe1H0oLksiNE816?= =?us-ascii?Q?Z8yYR50hfLCa1k2bquIwXlcE2mKhj1pDUqq0OENy+3dtAIijztkoxQyPn/LX?= =?us-ascii?Q?awMGWog0/S2LKsTi5dngCzmoW0YKwK76C2VrGOZ5YCR3u4hO2VFt4fyRFZqv?= =?us-ascii?Q?Pizxhu4yHMWzXHlts6aULKn3JjDq6zE1ipjjSj9V0nlrzk1NK39SXIK6/iXa?= =?us-ascii?Q?PulGcu94o DC2ecTeP0SeDQWbZnKZVZ/h5YN4fy4PMtm5VMqrY40A8CO/tzv4?= =?us-ascii?Q?A0WvUXKw4ROsjrkI?= Content-Language: en-us x-ms-exchange-organization-originalclientipaddress: 213.184.53.4 x-ms-exchange-organization-originalserveripaddress: 10.167.242.37 received-spf: Pass (mail1.rit.ee: domain of postmaster@AS8PR04CU009.outbound.protection.outlook.com designates 52.101.70.98 as permitted sender) identity=helo; client-ip=52.101.70.98; receiver=mail1.rit.ee; envelope-from="info@tervisekassa.ee"; x-sender="postmaster@AS8PR04CU009.outbound.protection.outlook.com"; x-conformance=spf_only; x-record-type="v=spf1"; x-record-text="v=spf1 ip4:40.92.0.0/15 ip4:40.107.0.0/16 ip4:52.100.0.0/15 ip4:52.102.0.0/16 ip4:52.103.0.0/17 ip4:104.47.0.0/17 ip6:2a01:111:f400::/48 ip6:2a01:111:f403::/49 ip6:2a01:111:f403:8000::/51 ip6:2a01:111:f403:c000::/51 ip6:2a01:111:f403:f000::/52 -all" X-OlkEid: 00000000D07AAE8E23CDBE4CA04D01CCD82FCB7E070034AD76187591974DBF6C4F76951C873A01000200000000005797C783AAECB34FA6C879FF487E64D9000000000C9800005B9D14E3AF73DB49A623A35BD7562189 X-CSE-ConnectionGUID: 8qe8XUXuTbyeuGhDTmemQg== X-CSE-MsgGUID: kKAwBNhYRS62qmMXpMpNGA== X-ThreatScanner-Verdict: Negative X-IPAS-Result: =?us-ascii?q?A0G1AwDlu9xpgWJGZTRaHAEBAQEBAQcBARIBAQQEAQGCE?= =?us-ascii?q?IE9MQEpKUEBRV8zB1GEWINPj1GKO5N2FikPAQEBAQEBCgJEDQQBAQMBA4UAH?= =?us-ascii?q?40PIAYBOBMBAgECAQEBAQEDAgMBAQEBAQEBAQEBAQsBAQEEAQEBAgEBAgQDA?= =?us-ascii?q?QEBAQIQAQE7Bw47hk8Ngls7cVEQAgIDAwM3AQEBAQEBAQEBAQEBAQEBAQEBA?= =?us-ascii?q?QEBAQEBAQEBAQEBAQEBAQEHAh8lCxwBAR0BAQEBFREdAQEvCAEYEwQBASsCI?= =?us-ascii?q?hEdISKCYYIkBBIDNgQQBpYij1oBgT0CAoooeoEygQGCDAEBBgQDAQN9TwI7B?= =?us-ascii?q?AHZFg2CVQMGCQGBKxiFPoJ5HwEBKoE1AQKCWoEhCQ8Bg397Qj94ViaFXIEaH?= =?us-ascii?q?xcMAQEBBYIHgy6CaYImehQdiXiFQoJCLAFVExcLBwWBZgN7CzI8Mh1kPz4XN?= =?us-ascii?q?FgbBwWBS4VHgWE4W4NsUCgKAwttPTcUGwSLQVwjgwiBQiuUQ5F+VgGgInGEJ?= =?us-ascii?q?jQJg0OXXAOGRhODcYMhiXKZVAuHeIsmhV2SEoYFkH8CBAIEBQIQAQc2gUkjg?= =?us-ascii?q?VyBBYMiTwMZD44hDBYcdwECgklswA5ANQI7AQECAQQCBwEKAQEDCQEBgWhQg?= =?us-ascii?q?lSNEGtgAQE?= X-Talos-CUID: =?us-ascii?q?9a23=3AW5ssCWuyCpbbjLt1r9prrPPP6It1a3CN/ErgPnO?= =?us-ascii?q?yGGt0Z725dVqd/Zprxp8=3D?= X-Talos-MUID: 9a23:+e6gTQoIEN4qDwTWMCYezzJBHdhCxaSfMntTy4wDnvmcEDRWFB7I2Q== X-IronPort-Anti-Spam-Filtered: true X-IronPort-AV: E=Sophos;i="6.23,177,1770588000"; d="scan'208,217";a="66823593" X-Amp-Result: SKIPPED(no attachment in message) X-Amp-File-Uploaded: False x-ms-exchange-senderadcheck: 1 x-ms-exchange-antispam-relay: 0 X-MS-Exchange-AntiSpam-MessageData-Original-ChunkCount: 1 X-MS-Exchange-AntiSpam-MessageData-Original-0: =?utf-8?B?eVhQYjNQd211WUN1eGM1MUlLVS96NzQvN3FBWWpXNFpEcEtSRG9zQi9YUlcv?= =?utf-8?B?SjhiNEtLN0NkVkN0dm1HMVl3cnRIWmZKMjVZajRYSjgzc3ZLNlhOZkdodW1x?= =?utf-8?B?OEZrVit6ZmhYOE9zRWR4VUwxZHpBN2x0bjFIYnhtT2xPZ2o2dHloblpyVkRV?= =?utf-8?B?RGs0azh5TzdNNGsxT3hLVHAraEIwK0E3Zk85UGlKTnhXQW10VVd3bTI4Ujc5?= =?utf-8?B?aStBY3hOTW04N2NkT0Zrc2krN2lyMkQ5a2lQNGRNVGFFNVBoaXRpV1FTZU1D?= =?utf-8?B?MmxXS3NsNit3MW55RDlvdXFVVk90c0Y5SGlZb1VNYktKclg2ek5LMEdQS2ll?= =?utf-8?B?UllFZ0hLK1JxQlIzc2pmR1Y4UDlhYzNvd0daSU1XWlFSWW5janpKOHNuRHJZ?= =?utf-8?B?WTh4T0k4UG4xSG5vcFRuaDBlL2hhakNndGxLSjFZYjhlWG45eUNJNmd0TnlN?= =?utf-8?B?RVJReWphcko0Mlc0R25UTHJ1Zm80bk1OYzdwNGIzQjN0eTJKTDlpNnlIREQv?= =?utf-8?B?c3hpRmRmUHV5RDU2a2xoSnI0MSsxejRJOWNGTUhOUWVEemF4MzhMVjl4RDBI?= =?utf-8?B?M0s1bjlzLzVDM3pMVmM5N0U1TTZWVWs0U2R3bGZFU1R5RHpROEhYMzV3M0NW?= =?utf-8?B?Uy9SMjNQUkZMa0x1VW0rajdmdHF4YjlLb1BBZXM1bGJBRXNmcllVbDVLcDk1?= =?utf-8?B?NTYwOVdObk85R2lUY1pUYVVBSXd1dEw5S01pVlo0UXhNdlU2OTEvWU1QWVVq?= =?utf-8?B?OUR5dEZubWRLNWd 6U2cza2d6ajZZSUErSW1YdnJ4R0FsQVI3Uk1kT3dGc0VQ?= =?utf-8?B?aDB6bFVQaU1MZE13L2hOdHg4R0s2eVljMG12NmduZ1VEeFU1NjRFRWFiRDZQ?= =?utf-8?B?NnhnM1B4WmZTcklkTEFudHh4cnhTWVptSW5rMm1BeFBxdjg0TG90UkJ1dkVr?= =?utf-8?B?L1JNMDJtWSswdkhUdjN0NUR5N1cyUkpnTm9iU2h6azdtcjZDVHUwd2NUeXh6?= =?utf-8?B?SnV5UjdmQng0MXFVNzFZODJHMjVmYy9NYTdzZ1J3UjBUYUNUUXA2K3VjRTZ6?= =?utf-8?B?SDJWOXdmVUF5bzZwNVhBOVhWWmFkQzBNaXpDbzV2NmxiR3pNMXNNbk1laFY4?= =?utf-8?B?YVBuWkp5cXZYd1FBV2g4c1JHVCtWU01JbkRtWjVlRkphd1A3b0FhdGU4TGY5?= =?utf-8?B?TTRzVlovdFdZd1JNcjJhcmZmNmlrVmRWUktyU1h1QlZweXJjTGpKeXNodE5B?= =?utf-8?B?K1VkRDJRcUgya2xSUkhndjVHWUhUSTlqNGpOVVNnaHNhQk14cFhySWM2c1Ew?= =?utf-8?B?YVdGTUZXQldkcnAyS1lDK0J0Njd6S2ZNOU5LbVFqQ2twUytJcDVqSlNVbjl4?= =?utf-8?B?ZmVSY080SEZMbVAzdi9PQmM3ZTI4d0JYenVZdjZZSkF6cDhjZElMSzh5SERS?= =?utf-8?B?U0pZV3pEMjhtbDZrSWtCZmpTdjJIUVJFcUlxd014b2taUzVFOVFvN2ZHT25V?= =?utf-8?B?ZEdTY0F6eEJBV1lEakkzWlhtOWxUa0RMT1NLV0FYQ2dkQVBtSzZpVlprUHpW?= =?utf-8?B?b2VJM3RjYzFnZVhoM2tGK1RlNWIrN3ZvSXFvaDl2 TEpjVENOcmxGNVpJWVF2?= =?utf-8?B?ZkM4VGdFY21jU1RYNVRNbksySjhEMkUrNVZxUjYrWEVsdG9vOVRvdjkvclE1?= =?utf-8?B?bWUrQkRlY2ZaclZ4QzY0bi9ZSldSVXlFc1hDM2oxS2hhaTBaa3Y2cW1oMFBi?= =?utf-8?B?cEl4cWV0TDFEcjhQSFFkMzcrRWw3Q0RGcklDNnI2ajB0eGI1TldmQlFZQzU1?= =?utf-8?B?T0t4U3dFbHdiMUJtcTFWT3dkWkJTNWNpZVdUTm9YdE85b3phVWUrdnNpNnlU?= =?utf-8?B?azdQaEpnbGJZbzZiUUZiUzNXMEFQYlhDOTZCdHoreTkzQUR0N3hsbVhRcU9S?= =?utf-8?B?WXl3S0dkeE5WMGEzT2I1dVpHRzB2WWVaZUppaUVkREdLOVVac3hSakFjdG9k?= =?utf-8?B?dXlac09SMjB3S3B2dmRuZVNFVHp5RWsrUTlOY2RMQVY1R1VVWW9PVTdmbmFq?= =?utf-8?B?RmlWbHc0OGxjR0UxV1FIZlFBOE1uS2ViOVFJVm5NT0tGcDNIamNhdEk1OS9n?= =?utf-8?B?aEFPaEFpTTByVVkyWTdOOWtuY01lemZrUm43SGdIY3pGNkFhbnEvN0o3cmQ3?= =?utf-8?B?eWZYM2FSTmxCQUlDME5neDRsT2w1V3hXaEt6OGYxc1ZCZHFUV0h0bzZaQkFy?= =?utf-8?Q?LVU2gekI+wEhEFvLqALRU1dq/VVvwp43AL7J1dezvw=3D?= X-EOPTenantAttributedMessage: 8fe098d2-428d-4bd4-9803-7195fe96f0e2:0 X-DisclaimerOO: 1 dkim-signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=tervisekassa.ee; s=selector2; h=From:Date:Subject:Message-ID:Content-Type:MIME-Version:X-MS-Exchange-SenderADCheck; bh=uu0zFGsexvy6/XOdZbUJ9zALkT+T2pldAayFjnH14Gg=; b=NSN5H3IGf8nPA6o3VF+DTRtijQ157uZE2E4uYBgN+ZrA55a7WNWpnxfLJFV2QLVj8zjXXQh1E/W2Xa94SEYP84La4PtSBP1BmJ0Pj+XHk4K+QM6mIWPEvza4LTf1vImWpW5S3ELTrodC8tbBO5DsWKnzlJQVOApMBblgHXC+n1/v+FY2kZY5+NFmtk5j0atnYh1MKjtgBbz5gmhhqcoIjk0IvCh2jfCE9YitYVDq+1/bEcotAH/h8OAPY5q9pvuENIk5EeYjKKJULcF2VkBnAy5h+/EG1SopFDwMT7rz9EI0F5e4CUZblBTbdOtFw6fxG2zZXesPwtBAqPj+BV5cSA== x-ms-exchange-messagesentrepresentingtype: 1 X-JIRA-FingerPrint: 994d543028cc0125c6142ebc4df2bf0c X-ClientProxiedBy: GV2PEPF0001A323.SWEP280.PROD.OUTLOOK.COM (2603:10a6:158:401::688) To BESP191MB2978.EURP191.PROD.OUTLOOK.COM (2603:10a6:b10:f2::13) This is a multipart message in MIME format. ------=_NextPart_000_0065_01DCCB45.7F9B0500 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere Tervisekassa on teadlik meditsiinilise transpordi teenuse (kood 3071) arvestuse ja korraldusega seotud kitsaskohtadest, sh erinevusest patsiendipõhise arvelduse ja sõidupõhise teenuse osutamise vahel. Oleme nõus, et kirjeldatud olukorrad võivad vähendada kulude läbipaistvust ja raskendada teenuse tegeliku mahu seostamist arveldatud summadega. Hetkel kehtiv arvestusmudel lähtub patsiendipõhisest rahastamisest, kuid Tervisekassa analüüsib koostöös teenuseosutajate ja partneritega võimalikke muudatusi, et parandada süsteemi läbipaistvust, kontrollitavust ja kulutõhusust. Teie toodud tähelepanekud on selles protsessis asjakohased ning võetakse arvesse edasiste lahenduste kujundamisel. Tervist soovides Signe Borissov Teie viimane pöördumine: From: Med Transport Sent: Thursday, March 19, 2026 8:27 PM To: Info - SOM Subject: täiendav sisend meditsiinilise transpordi arvelduse korralduse kohta Lugupeetud Sotsiaalministeerium Pöördun Teie poole seoses meditsiinilise transpordi teenuse (Tervisekassa kood 3071) arvelduse korraldusega. Olen varasemalt sellel teemal pöördunud, kuid vahepeal on lisandunud täiendav teave ning avalik käsitlus, mille põhjal on selgunud, et tegemist ei ole üksikjuhtumitega, vaid süsteemse puudujäägiga. On tuvastatud ja raviasutuste poolt kinnitatud, et: – meditsiinilise transpordi teenuse arvestus toimub patsiendipõhiselt, samas kui teenuse osutamine toimub sõidupõhiselt; – praktikas transporditakse ühes sõidukis samaaegselt mitu patsienti, kuid iga patsiendi kohta esitatakse eraldi arve; – selline arvestusloogika toob kaasa olukorrad, kus ühe tegeliku sõidu eest esitatakse mitmekordsed arved; – arveldamise ja transpordi korraldamise funktsioonid on lahutatud, mistõttu puudub terviklik ja kontrollitav seos konkreetse sõidu ja esitatud arvete vahel; – sarnane arvestuspraktika esineb raviasutustes üle Eesti ning ei piirdu üksikjuhtumitega. Eeltoodu kinnitab, et tegemist on süsteemse arvestusloogikaga, mis võimaldab mitmekordset arveldamist ühe tegeliku sõidu eest ning muudab avaliku raha tegeliku kasutuse kontrollimise sisuliselt võimatuks. Selline korraldus ei taga avalike vahendite sihipärast ja läbipaistvat kasutamist ning loob olukorra, kus teenuse tegelik maht ja selle eest makstav tasu ei ole omavahel üheselt seostatavad. Arvestades, et meditsiinilise transpordi teenuse korraldust ja rahastamist on lähiaastatel kavas edasi arendada, on oluline, et nimetatud puudujääk oleks regulatsiooni kujundamisel arvesse võetud ja kõrvaldatud. Käesoleva pöördumise eesmärk on juhtida tähelepanu süsteemsele probleemile, mis mõjutab otseselt avalike vahendite kasutamise läbipaistvust, kontrollitavust ja efektiivsust. Lugupidamisega Tartu Meditsiiniline Transport OÜ Signe Borissov TTO võrgustik E: partner@tervisekassa.ee Liivalaia 36, Tallinn E-kiri ja selle manused võivad sisaldada konfidentsiaalseid andmeid ning seda võivad kasutada vaid kirja saajad. Palun ärge edastage ega avaldage kirjas olevat teavet teistele inimestele ilma saatja loata. Juhul kui olete saanud e-kirja eksituse tõttu, teavitage palun kohe saatjat ning kustutage kiri. This e-mail and any attachments may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by return e-mail, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be illegal. ------=_NextPart_000_0065_01DCCB45.7F9B0500 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte = avada.

Tere

Tervisekassa on teadlik meditsiinilise transpordi teenuse (kood 3071) = arvestuse ja korraldusega seotud kitsaskohtadest, sh erinevusest = patsiendip=C3=B5hise arvelduse ja s=C3=B5idup=C3=B5hise teenuse = osutamise vahel. Oleme n=C3=B5us, et kirjeldatud olukorrad v=C3=B5ivad = v=C3=A4hendada kulude l=C3=A4bipaistvust ja raskendada teenuse tegeliku mahu seostamist = arveldatud summadega.

Hetkel kehtiv arvestusmudel l=C3=A4htub patsiendip=C3=B5hisest = rahastamisest, kuid Tervisekassa anal=C3=BC=C3=BCsib koost=C3=B6=C3=B6s = teenuseosutajate ja partneritega v=C3=B5imalikke muudatusi, et parandada = s=C3=BCsteemi l=C3=A4bipaistvust, kontrollitavust ja kulut=C3=B5husust. = Teie toodud t=C3=A4helepanekud on selles protsessis asjakohased ning v=C3=B5etakse arvesse edasiste = lahenduste kujundamisel.

Tervist soovides
Signe Borissov

Teie viimane = p=C3=B6=C3=B6rdumine:

From: Med Transport = <medtransportteenusoy@gmail.com>
Sent: Thursday, March 19, 2026 8:27 PM
To: Info - SOM <info@sm.ee>
Subject: t=C3=A4iendav sisend meditsiinilise transpordi = arvelduse korralduse kohta

Lugupeetud Sotsiaalministeerium

P=C3=B6=C3=B6rdun Teie poole seoses meditsiinilise transpordi teenuse = (Tervisekassa kood 3071) arvelduse korraldusega.

Olen varasemalt sellel teemal p=C3=B6=C3=B6rdunud, kuid vahepeal on = lisandunud t=C3=A4iendav teave ning avalik k=C3=A4sitlus, mille = p=C3=B5hjal on selgunud, et tegemist ei ole =C3=BCksikjuhtumitega, vaid = s=C3=BCsteemse puuduj=C3=A4=C3=A4giga.

On tuvastatud ja raviasutuste poolt kinnitatud, et:
=E2=80=93 meditsiinilise transpordi teenuse arvestus toimub = patsiendip=C3=B5hiselt, samas kui teenuse osutamine toimub = s=C3=B5idup=C3=B5hiselt;
=E2=80=93 praktikas transporditakse =C3=BChes s=C3=B5idukis samaaegselt = mitu patsienti, kuid iga patsiendi kohta esitatakse eraldi arve;
=E2=80=93 selline arvestusloogika toob kaasa olukorrad, kus =C3=BChe = tegeliku s=C3=B5idu eest esitatakse mitmekordsed arved;
=E2=80=93 arveldamise ja transpordi korraldamise funktsioonid on = lahutatud, mist=C3=B5ttu puudub terviklik ja kontrollitav seos = konkreetse s=C3=B5idu ja esitatud arvete vahel;
=E2=80=93 sarnane arvestuspraktika esineb raviasutustes =C3=BCle Eesti = ning ei piirdu =C3=BCksikjuhtumitega.

Eeltoodu kinnitab, et tegemist on s=C3=BCsteemse arvestusloogikaga, = mis v=C3=B5imaldab mitmekordset arveldamist =C3=BChe tegeliku s=C3=B5idu = eest ning muudab avaliku raha tegeliku kasutuse kontrollimise sisuliselt = v=C3=B5imatuks.

Selline korraldus ei taga avalike vahendite sihip=C3=A4rast ja = l=C3=A4bipaistvat kasutamist ning loob olukorra, kus teenuse tegelik = maht ja selle eest makstav tasu ei ole omavahel =C3=BCheselt = seostatavad.

Arvestades, et meditsiinilise transpordi teenuse korraldust ja = rahastamist on l=C3=A4hiaastatel kavas edasi arendada, on oluline, et = nimetatud puuduj=C3=A4=C3=A4k oleks regulatsiooni kujundamisel arvesse = v=C3=B5etud ja k=C3=B5rvaldatud.

K=C3=A4esoleva p=C3=B6=C3=B6rdumise eesm=C3=A4rk on juhtida = t=C3=A4helepanu s=C3=BCsteemsele probleemile, mis m=C3=B5jutab otseselt = avalike vahendite kasutamise l=C3=A4bipaistvust, kontrollitavust ja = efektiivsust.

Lugupidamisega
Tartu Meditsiiniline Transport O=C3=9C

 

3D"TervisekassaLogoBlacksmall.jpg" 3D"spacer.jpg"

Signe = Borissov
TTO = v=C3=B5rgustik

E: = partner@tervisekassa.ee
Liivalaia 36, Tallinn

3D"fb_ico.jpg" 3D"homepage_ico.jpg" 3D"email_ico.jpg" 3D"youtube_ico.jpg" 3D"blogi_ico.jpg"

E-kiri = ja selle manused v=C3=B5ivad sisaldada konfidentsiaalseid andmeid ning = seda v=C3=B5ivad kasutada vaid kirja saajad. Palun =C3=A4rge edastage = ega avaldage kirjas olevat teavet teistele inimestele ilma saatja loata. Juhul kui olete saanud e-kirja eksituse t=C3=B5ttu, teavitage = palun kohe saatjat ning kustutage kiri.

This = e-mail and any attachments may contain confidential and privileged = information. If you are not the intended recipient, please notify the = sender immediately by return e-mail, delete this e-mail and destroy any copies. Any dissemination or use of this information by = a person other than the intended recipient is unauthorized and may be = illegal.

------=_NextPart_000_0065_01DCCB45.7F9B0500--